LGVN Q2 2024 Earnings — Longeveron Inc. Revenue & Financial Results | Market Cap Arena

LGVNLongeveron Inc.

$20M

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$468,000+115.7% YoY

Gross Profit

$344,00073.5% margin

Operating Income

-$4M-747.9% margin

Net Income

-$3M-729.3% margin

EPS (Diluted)

$-1.83

QoQ Revenue Growth

-14.6%

Cash Flow

Operating Cash Flow

-$5M

Free Cash Flow

-$5M

Stock-Based Comp.

$200,000

Balance Sheet

Total Assets

$19M

Total Liabilities

$4M

Stockholders' Equity

$15M

Cash & Equivalents

$12M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$468,000	$217,000	+115.7%
Gross Profit	$344,000	$93,000	+269.9%
Operating Income	-$4M	-$6M	+38.7%
Net Income	-$3M	-$6M	+39.4%